Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1994 1
1996 1
1998 1
1999 1
2000 9
2001 5
2002 12
2003 7
2004 5
2005 11
2006 18
2007 19
2008 17
2009 20
2010 17
2011 9
2012 17
2013 14
2014 13
2015 8
2016 8
2017 15
2018 11
2019 6
2020 10
2021 10
2022 11
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
Behçet Syndrome.
Hatemi G, Uçar D, Uygunoğlu U, Yazici H, Yazici Y. Hatemi G, et al. Among authors: yazici y. Rheum Dis Clin North Am. 2023 Aug;49(3):585-602. doi: 10.1016/j.rdc.2023.03.010. Epub 2023 May 2. Rheum Dis Clin North Am. 2023. PMID: 37331734 Review.
Behçet syndrome.
Yazici Y, Hatemi G, Bodaghi B, Cheon JH, Suzuki N, Ambrose N, Yazici H. Yazici Y, et al. Nat Rev Dis Primers. 2021 Sep 16;7(1):67. doi: 10.1038/s41572-021-00301-1. Nat Rev Dis Primers. 2021. PMID: 34531393 Review.
Editorial: Introduction, Vasculitis 2021.
Yazici H, Yazici Y. Yazici H, et al. Among authors: yazici y. Curr Opin Rheumatol. 2022 Jan 1;34(1):1-3. doi: 10.1097/BOR.0000000000000856. Curr Opin Rheumatol. 2022. PMID: 34819486 No abstract available.
Introduction, Vasculitis 2023.
Yazici H, Yazici Y. Yazici H, et al. Among authors: yazici y. Curr Opin Rheumatol. 2024 Jan 1;36(1):1-2. doi: 10.1097/BOR.0000000000000984. Epub 2023 Nov 30. Curr Opin Rheumatol. 2024. PMID: 38015004 No abstract available.
The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
Tam BY, Chiu K, Chung H, Bossard C, Nguyen JD, Creger E, Eastman BW, Mak CC, Ibanez M, Ghias A, Cahiwat J, Do L, Cho S, Nguyen J, Deshmukh V, Stewart J, Chen CW, Barroga C, Dellamary L, Kc SK, Phalen TJ, Hood J, Cha S, Yazici Y. Tam BY, et al. Among authors: yazici y. Cancer Lett. 2020 Mar 31;473:186-197. doi: 10.1016/j.canlet.2019.09.009. Epub 2019 Sep 24. Cancer Lett. 2020. PMID: 31560935 Free article.
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology. Saag KG, et al. Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721. Arthritis Rheum. 2008. PMID: 18512708 Free article. No abstract available.
Biomarkers in vasculitis.
Hatemi G, Esatoglu SN, Yazici Y. Hatemi G, et al. Among authors: yazici y. Curr Opin Rheumatol. 2018 Jan;30(1):30-35. doi: 10.1097/BOR.0000000000000447. Curr Opin Rheumatol. 2018. PMID: 28937415 Review.
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V, O'Green AL, Bossard C, Seo T, Lamangan L, Ibanez M, Ghias A, Lai C, Do L, Cho S, Cahiwat J, Chiu K, Pedraza M, Anderson S, Harris R, Dellamary L, Kc S, Barroga C, Melchior B, Tam B, Kennedy S, Tambiah J, Hood J, Yazici Y. Deshmukh V, et al. Among authors: yazici y. Osteoarthritis Cartilage. 2019 Sep;27(9):1347-1360. doi: 10.1016/j.joca.2019.05.006. Epub 2019 May 25. Osteoarthritis Cartilage. 2019. PMID: 31132406 Free article.
274 results